William Wade

Experience

1. Founding Investor and Member, Board of Directors

   Oscillo Biosciences

   Nov 2017 — Present · Farmington, CT, US

   In the US today, nearly 6 million people are suffering from dementia due to Alzheimer’s Disease, and this number is expected to more than double to almost 14 million in the next 30 years. Another 12 million people suffer from Mild Cognitive Impairment, a precursor to Alzheimer’s dementia, and 25 million people have preclinical Alzheimer’s disease, the biomarkers are there, but they are not yet experiencing symptoms. That’s 43 million people in the US alone. Worldwide, more than 600 million people are in one of these disease stages. It is a global epidemic. And despite billions spent on research, there is still no cure for Alzheimer’s disease, and not even a neuroprotective treatment. At Oscilloscape, we are taking a different approach. We are now testing a music-based digital intervention for Alzheimer’s Disease that combines the power of music with the latest breakthroughs in neuroscience. SynchronyGamma will help patients delay the onset of dementia by stimulating brain rhythms using a world wide patented process engaging science, personalized music and uniquely and proprietary synchronized lighting methods. Oscilloscape\'s patented technology enables nonlinear signal processing to be effectively and efficiently implemented in hardware and software. Our novel technology is based on research in auditory neuroscience, enabling signal processing, pattern analysis, and learning using neural networks that resonate to acoustic signals. Reach us at c••••••@oscilloscape.com. Our technology is protected by US patents 7,376,562 and 8,583,442 to Oscilloscape, LLC; other US and International patents pending.

Education

• University of New Hampshire

  Restaurant Management

  1980 — 1982